{"id":235458,"date":"2026-04-17T18:14:06","date_gmt":"2026-04-17T23:14:06","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/04\/fdg-pet-for-estimating-outcomes-after-initial-treatment-for-metastatic-breast-cancer"},"modified":"2026-04-17T18:14:06","modified_gmt":"2026-04-17T23:14:06","slug":"fdg-pet-for-estimating-outcomes-after-initial-treatment-for-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/04\/fdg-pet-for-estimating-outcomes-after-initial-treatment-for-metastatic-breast-cancer","title":{"rendered":"FDG-PET for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/fdg-pet-for-estimating-outcomes-after-initial-treatment-for-metastatic-breast-cancer.jpg\"><\/a><\/p>\n<p>Among patients with newly diagnosed metastatic BreastCancer (MBC), a clinical cohort trial evaluated early treatment response using 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) compared with standard computed tomography (CT) assessment.<\/p>\n<p>FDG-PET after only 2 weeks of treatment identified patients with MBC with distinct long-term outcomes. Incorporating early FDG-PET can improve outcome estimation of standard CT assessment.<\/p>\n<hr>\n<p>Question Does repeated <sup>18 <\/sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) after 2 weeks of treatment improve outcome estimation in metastatic breast cancer compared to standard diagnostics?<\/p>\n<p><strong>Findings<\/strong> This clinical cohort trial including 200 patients found that those without disease progression on early FDG-PET had better median progression-free survival (PFS) and overall survival (OS) than patients with disease progression. Among patients without progression on computed tomography (CT) after 8 weeks, those with progression on early FDG-PET had a median OS of 22.3 months, whereas patients without progression on both CT and early FDG-PET had an OS of 50.1 months.<\/p>\n<p><strong>Meaning<\/strong> Early FDG-PET imaging may improve outcome estimation in newly diagnosed metastatic breast cancer compared to standard CT alone.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Among patients with newly diagnosed metastatic BreastCancer (MBC), a clinical cohort trial evaluated early treatment response using 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) compared with standard computed tomography (CT) assessment. FDG-PET after only 2 weeks of treatment identified patients with MBC with distinct long-term outcomes. Incorporating early FDG-PET can improve outcome estimation of standard CT assessment. [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-235458","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/235458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=235458"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/235458\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=235458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=235458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=235458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}